The talazoparib beyond BRCA (TBB) is an open-label phase II trial, to evaluate talazoparib in patients with pretreated HER2-ve ABC (n = 13) or other solid tumors (n = 7) with mutations in HRR genes other than BRCA1 and BRCA2. In patients with BC the ORR was 31% and the CBR≥6m was 54%. This evidence concerns the gene ERBB2 and breast cancer.